3-(环戊氧基)-4-甲氧基苯胺 | 154464-26-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-(环戊氧基)-4-甲氧基苯胺
• 英文名称: 3-(cyclopentyloxy)-4-methoxyaniline
• 英文别名: 3-cyclopentyloxy-4-methoxyaniline
• CAS: 154464-26-3
• 化学式: C₁₂H₁₇NO₂
• mdl: MFCD00219843
• 分子量: 207.272
• InChiKey: RRZIWWXZGHOMDM-UHFFFAOYSA-N

物化性质

• 沸点：
  342.6±22.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38

SDS

Name:	3-(Cyclopentyloxy)-4-methoxyaniline 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	154464-26-3

Section 1 - Chemical Product MSDS Name:3-(Cyclopentyloxy)-4-methoxyaniline 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
154464-26-3	3-(Cyclopentyloxy)-4-methoxyaniline	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Keep refrigerated. (Store below 4C/39F.) Store in a tightly closed container. Store in a dry area. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 154464-26-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 128 - 130 deg C @0.3mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H17NO2
Molecular Weight: 207.27

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Acids, acid chlorides, oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 154464-26-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(Cyclopentyloxy)-4-methoxyaniline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 154464-26-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 154464-26-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 154464-26-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(环戊氧基)-4-甲氧基苯胺 在 ammonium tetrafluoroborate 、 palladium 10% on activated carbon 、 氢气 、 sodium acetate 、 palladium diacetate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 sodium nitrite 作用下， 以 甲醇 、 乙醇 、 水 、 叔丁醇 为溶剂， 60.0 ℃ 、1.0 MPa 条件下， 反应 37.5h， 生成 咯利普兰
  参考文献：
  名称：

  从扑热息痛到咯利普兰及其衍生物：脱乙酰基-重氮化序列和钯催化的松田-Heck反应的应用

  摘要：

  摘要 描述了从流行的止痛药4-乙酰氨基苯酚（扑热息痛）六步合成抗抑郁剂咯利普兰。这些步骤包括芳族核的氧化功能化，通过脱乙酰基-重氮化作用，重田松树-Heck反应，共轭添加硝基甲烷和氢化环化形成重氮盐。 描述了从流行的止痛药4-乙酰氨基苯酚（扑热息痛）六步合成抗抑郁剂咯利普兰。这些步骤包括芳族核的氧化功能化，通过脱乙酰基-重氮化作用，重田松树-Heck反应，共轭添加硝基甲烷和氢化环化形成重氮盐。

  DOI：

  10.1055/s-0032-1316874
• 作为产物：
  描述：

  4'-甲氧基乙酰苯胺 在 盐酸 、 水 、 碳酸氢钠 、 potassium carbonate 、 potassium iodide 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.0h， 生成 3-(环戊氧基)-4-甲氧基苯胺
  参考文献：
  名称：

  从扑热息痛到咯利普兰及其衍生物：脱乙酰基-重氮化序列和钯催化的松田-Heck反应的应用

  摘要：

  摘要 描述了从流行的止痛药4-乙酰氨基苯酚（扑热息痛）六步合成抗抑郁剂咯利普兰。这些步骤包括芳族核的氧化功能化，通过脱乙酰基-重氮化作用，重田松树-Heck反应，共轭添加硝基甲烷和氢化环化形成重氮盐。 描述了从流行的止痛药4-乙酰氨基苯酚（扑热息痛）六步合成抗抑郁剂咯利普兰。这些步骤包括芳族核的氧化功能化，通过脱乙酰基-重氮化作用，重田松树-Heck反应，共轭添加硝基甲烷和氢化环化形成重氮盐。

  DOI：

  10.1055/s-0032-1316874

文献信息

• Transition metal free intramolecular selective oxidative C(sp³)–N coupling: synthesis of N-aryl-isoindolinones from 2-alkylbenzamides
  作者：Ajay Verma、Saket Patel、Meenakshi Meenakshi、Amit Kumar、Abhimanyu Yadav、Shailesh Kumar、Sadhan Jana、Shubham Sharma、Ch. Durga Prasad、Sangit Kumar

  DOI：10.1039/c4cc08717h

  日期：——

  isoindolinones including indoprofen and DWP205190 drugs from 2-alkylbenzamide substrates by transition metal-free intramolecular selective oxidative coupling of C(sp(3))-H and N-H bonds utilizing iodine, potassium carbonate and di-tert-butyl peroxide in acetonitrile at 110-140 degrees C.

  通过使用碘，碳酸钾通过C（sp（3））-H和NH键的无过渡金属的分子内选择性氧化偶联，已开发出一种用于从2-烷基苯甲酰胺底物制备生物学上重要的异吲哚啉酮（包括吲哚洛芬和DWP205190药物）的合成方法和二叔丁基过氧化物的乙腈溶液，温度为110-140摄氏度。
• [EN] PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS<br/>[FR] INHIBITEURS DE PHOSPHODIESTERASE 4 COMPRENANT DES ANALOGUES DE DIPHENYLAMINE ET D'ANILINE N-SUBSTITUES
  申请人：MEMORY PHARM CORP

  公开号：WO2004009552A1

  公开（公告）日：2004-01-29

  PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula (I): wherein R1, R2 R 3 and R4 are as defined herein.

  PDE4抑制作用是通过新型化合物实现的，例如N-取代苯胺和二苯胺类似物。本发明的化合物为公式(I)：其中R1，R2，R3和R4如本文所述定义。
• Compounds containing phenyl linked to aryl or heteroaryl by an
  申请人：Rhone-Poulenc Rorer Limited

  公开号：US05935978A1

  公开（公告）日：1999-08-10

  This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.

  这项发明涉及苯基化合物的药用，这些化合物通过各种连接与芳基团相连，用于抑制肿瘤坏死因子。该发明还涉及这些化合物、它们的制备以及含有这些化合物的药物组合物。此外，这项发明还涉及这些化合物的药用，用于抑制环磷酸腺苷磷酸二酯酶。
• [EN] NEW MACROLIDES AND THEIR USE<br/>[FR] NOUVEAUX MACROLIDES ET LEUR UTILISATION
  申请人：BASILEA PHARMACEUTICA AG

  公开号：WO2009106419A1

  公开（公告）日：2009-09-03

  The invention relates to macrolide compounds of formula (I),the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with anti-inflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.

  本发明涉及公式(I)的大环内酯化合物，以及所述化合物作为药物的应用，特别是用于治疗或预防炎性和过敏性疾病，包含所述化合物的药物组合物，以及它们的制备过程。本发明特别涉及主要通过抑制磷酸二酯酶4（PDE4）介导抗炎活性的大环内酯化合物，这使得它们可用于治疗和/或预防诸如慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、特应性皮炎、炎症性肠病或增殖性疾病，例如癌症等炎性和过敏性疾病。
• 3-anilino-2-cycloalkenone derivatives
  申请人：Nikken Chemicals Co., Ltd.

  公开号：US06235736B1

  公开（公告）日：2001-05-22

  A 3-anilino-2-cycloalkenone derivative of the formula (I): wherein, R1 represents a C1 to C8 alkyl group, which may have a substituent, except for a methyl group, a C3 to C7 cycloalkyl group, a 3-tetrahydrofuryl group, an 2-indanyl group, etc., R2 represents a C1 to C4 alkyl group, R3 represents a hydrogen atom, a C3 to C7 alkyl group, which may have a substituent, a C3 to C7 cycloalkyl group, etc., R4 represents a hydrogen atom, a C1 to C5 alkyl group, which may have a substituent, a halogen atom, etc., R5, R6, R7, and R8 independently represent a hydrogen atom, a C1 to C5 alkyl group, which may have a substituent, etc., X represents —(CR11R12)n—, wherein n is 0 to 2, R11 and R12 independently represent a hydrogen atom, a C1 to C5 alkyl group, which may have a substituent, etc. or —NR13— wherein R13 represents a hydrogen atom or a C1 to C5 alkyl group, which may have a substituent, and its optical isomers or their pharmaceutically acceptable salts or their hydrates or solvates.

  3-苯胺-2-环烯酮衍生物的公式(I)：其中，R1代表一个C1至C8的烷基，可以有取代基，但不包括甲基，一个C3至C7的环烷基，一个3-四氢呋基，一个2-茚基等；R2代表一个C1至C4的烷基；R3代表一个氢原子，一个C3至C7的烷基，可以有取代基，一个C3至C7的环烷基等；R4代表一个氢原子，一个C1至C5的烷基，可以有取代基，一个卤素原子等；R5、R6、R7和R8各自独立代表一个氢原子，一个C1至C5的烷基，可以有取代基等；X代表—(CR11R12)n—，其中n是0至2，R11和R12各自独立代表一个氢原子，一个C1至C5的烷基，可以有取代基等，或者—NR13—其中R13代表一个氢原子或一个C1至C5的烷基，可以有取代基，以及它的光学异构体或它们的药用可接受盐或它们的水合物或溶剂化物。